Nektar Therapeutics’ pegylation strategy on IL-2 promised to resolve one of the thorniest hurdles in cancer R&D, inspiring a record $1.85 billion deal by a group of cancer research specialists at Bristol-Myers Squibb who were intensely excited by NKTR-214 and the prospect of advancing a killer approach to checkpoint combos.
But an analyst who’s played a key role behind some of the most effective short attacks in biotech in recent years has just fired a torpedo at the mother ship, hoping to persuade investors that NKTR-214 — one of the most closely followed cancer drugs now in the clinic — is absolutely worthless.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 41,700+ biopharma pros who read Endpoints News by email every day.Free Subscription